According to EU-Startups, myTomorrows just closed a €25 million growth equity investment from Avego to accelerate global expansion of its AI-driven platform that connects patients with pre-approval treatments. The Dutch HealthTech company, founded in 2012 and headquartered in Amsterdam, has already supported over 16,900 patients and 2,800 physicians across 340+ sites in 133 countries. CEO Michel van Harten called this “a pivotal step in our journey to give every patient a fair shot at tomorrow’s therapies.” The funding represents one of the larger Dutch HealthTech rounds of 2025 and comes as the company addresses the gap facing 300 million patients worldwide who lack approved treatment options.
The European HealthTech funding landscape
This isn’t happening in isolation. 2025 is shaping up to be a solid year for European HealthTech funding, with several notable rounds happening around the same time. Belgium’s Sequana Medical grabbed €24 million for its fluid-management device, France’s ArcaScience raised €6 million for AI drug development tools, and Finland’s CurifyLabs got €6.7 million for personalized medicine production. But here’s the thing – myTomorrows stands out because they’re not developing the therapies themselves. They’re building the bridge between patients who desperately need treatments and the pharmaceutical companies developing them. It’s essentially matchmaking at scale, but with life-saving implications.
Why this particular model matters
Look, the traditional drug development pipeline is brutally slow. We’re talking years, sometimes decades, between discovery and approval. Meanwhile, patients with serious conditions are left waiting, often with no good options. myTomorrows is essentially creating a parallel track – giving physicians and patients access to therapies that show promise but haven’t cleared all the regulatory hurdles yet. Their platform connects everyone: doctors looking for options, trial sites needing participants, and pharma companies wanting real-world data. It’s a win-win-win, but the biggest winner is potentially the patient who gets access to something that might help when nothing else has.
Where this is all heading
So what does €25 million actually buy in this space? Global expansion for starters – they already have a New York office, but expect to see more international presence. More importantly, it fuels their AI capabilities. Think about the data they’re sitting on: thousands of patient cases, treatment outcomes, physician patterns. That’s gold for improving matching algorithms and potentially even influencing drug development itself. The company also plans to strengthen collaborations with industry partners to shorten clinical development timelines. Basically, they’re positioning themselves as an essential infrastructure player in the pharmaceutical ecosystem. Not just connecting dots, but actively shaping how drugs move from lab to patient.
The bigger picture for healthcare
This investment signals something important about where healthcare is heading. We’re moving toward more personalized, on-demand treatment access. The old model of “wait for FDA/EMA approval or nothing” is being challenged by platforms that create alternative pathways. And the timing couldn’t be better – with over 10,000 therapies in development globally, the coordination problem is becoming massive. Companies like myTomorrows are essentially building the operating system for experimental medicine. The real question is whether regulators will keep pace with these new access models. But one thing’s clear: patients aren’t willing to wait quietly anymore, and investors are betting that platforms facilitating earlier access represent the future.
